307 related articles for article (PubMed ID: 21888257)
21. Overweight/Obesity and Monoclonal Gammopathy of Undetermined Significance.
Georgakopoulou R; Andrikopoulou A; Sergentanis TN; Fiste O; Zagouri F; Gavriatopoulou M; Psaltopoulou T; Kastritis E; Terpos E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):361-367. PubMed ID: 33582053
[TBL] [Abstract][Full Text] [Related]
22. UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).
Bird J; Behrens J; Westin J; Turesson I; Drayson M; Beetham R; D'Sa S; Soutar R; Waage A; Gulbrandsen N; Gregersen H; Low E;
Br J Haematol; 2009 Oct; 147(1):22-42. PubMed ID: 19673884
[No Abstract] [Full Text] [Related]
23. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA
Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.
Kyle RA; Rajkumar SV
JAMA Oncol; 2015 May; 1(2):174-5. PubMed ID: 26181018
[No Abstract] [Full Text] [Related]
25. Monoclonal Gammopathy of Undetermined Significance.
Gonsalves WI; Rajkumar SV
Ann Intern Med; 2022 Dec; 175(12):ITC177-ITC192. PubMed ID: 36508741
[TBL] [Abstract][Full Text] [Related]
26. The screening imperative for multiple myeloma.
Rajkumar SV
Nature; 2020 Nov; 587(7835):S63. PubMed ID: 33235369
[No Abstract] [Full Text] [Related]
27. Smoldering multiple myeloma: present position and potential promises.
Tageja N; Manasanch EE; Korde N; Kwok M; Mailankody S; Bhutani M; Roschewski M; Landgren O
Eur J Haematol; 2014 Jan; 92(1):1-12. PubMed ID: 24112232
[TBL] [Abstract][Full Text] [Related]
28. [Multiple myeloma after monoclonal gammopathy of uncertain significance. Study of 10 patients].
Salgado C; Bladé J; López-Guillermo A; Cervantes F; Montserrat E; Rozman C
Sangre (Barc); 1993 Oct; 38(5):371-4. PubMed ID: 8140498
[TBL] [Abstract][Full Text] [Related]
29. Monoclonal gammopathies of undetermined significance.
Kyle RA; Rajkumar SV
Best Pract Res Clin Haematol; 2005; 18(4):689-707. PubMed ID: 16026745
[TBL] [Abstract][Full Text] [Related]
30. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
31. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.
Kyle RA; Durie BG; Rajkumar SV; Landgren O; Blade J; Merlini G; Kröger N; Einsele H; Vesole DH; Dimopoulos M; San Miguel J; Avet-Loiseau H; Hajek R; Chen WM; Anderson KC; Ludwig H; Sonneveld P; Pavlovsky S; Palumbo A; Richardson PG; Barlogie B; Greipp P; Vescio R; Turesson I; Westin J; Boccadoro M;
Leukemia; 2010 Jun; 24(6):1121-7. PubMed ID: 20410922
[TBL] [Abstract][Full Text] [Related]
32. Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events.
Landgren O
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):662-672. PubMed ID: 34889381
[TBL] [Abstract][Full Text] [Related]
33. Clinical practice. Monoclonal gammopathy of undetermined significance.
Bladé J
N Engl J Med; 2006 Dec; 355(26):2765-70. PubMed ID: 17192542
[No Abstract] [Full Text] [Related]
34. Risk Stratification of Precursors to Multiple Myeloma in 2020.
Chudasama R; Barth P
R I Med J (2013); 2020 Apr; 103(3):46-47. PubMed ID: 32236162
[TBL] [Abstract][Full Text] [Related]
35. Smoldering multiple myeloma current treatment algorithms.
Rajkumar SV; Kumar S; Lonial S; Mateos MV
Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
[TBL] [Abstract][Full Text] [Related]
36. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
Anagnostopoulos A; Evangelopoulou A; Sotou D; Gika D; Mitsibounas D; Dimopoulos MA
Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma in Older Adults.
Guerard EJ; Tuchman SA
Clin Geriatr Med; 2016 Feb; 32(1):191-205. PubMed ID: 26614868
[TBL] [Abstract][Full Text] [Related]
38. Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies.
Altrock PM; Ferlic J; Galla T; Tomasson MH; Michor F
JCO Clin Cancer Inform; 2018 Dec; 2():1-12. PubMed ID: 30652561
[TBL] [Abstract][Full Text] [Related]
39. [Benign monoclonal gammopathy].
Shirota T; Kondo M; Uchida H; Ito H
Nihon Rinsho; 1995 Mar; 53(3):720-4. PubMed ID: 7699912
[TBL] [Abstract][Full Text] [Related]
40. It is worth the weight: obesity and the transition from monoclonal gammopathy of undetermined significance to multiple myeloma.
Choa R; Panaroni C; Bhatia R; Raje N
Blood Adv; 2023 Sep; 7(18):5510-5523. PubMed ID: 37493975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
